Replies to post #110798 on Amarantus Bioscience Holdings Inc (AMBS)

[tsuguy]

"The numbers for Lympro have essentially never changed in 12 + years."

Hello, that is the point and proof of stable results.

[joboggi]

The key is the sen, for research. Period. You don't want people in your study who do not have the disease. That lympro can add anything to the process remains to be seen.

and claiming a difference between version one and 2 based on 30 people so far is unwise.

AND assuming that a team would get two tests instead of one is ludicrous.

There is nothing supporting the use of Lympro WIDELY in research published to date, and there is no chance that it will be used to screen folks who are not in research.

saying it will happen will not make it happen. It is like saying that Nanosomix since it does not have what is considered a guru, will not have a good test. Indeed their test serum p tau, is at least two years ahead of AMBS.

[GS1]

Any product in developement stage is first tested for quality and not quantity and Lympro is tested for stable and consistent results with different types of patients. Also during developement phase they have to perform different types of tests (stimulation levels, incubation times) to tune assay performance. They have to establish these guidelines before full commercialization of product.Once guidelines are established and assay parameters are tuned it will become easier to test in large number of patients.


All I care about is sensitivity, that is what Big Pharma wants. In recent LP-002 study they have improved sensitivity to 90% which is fantastic.

$$$AMBS$$$